Research
NO LONGER ENROLLING If you are diagnosed with LGI1 autoimmune encephalitis (LGI1) or are the caregiver of someone with LGI1, you may qualify to participate in this study conducted by Fulcrum Research Group. The goal of the study is to better understand the patient experience with LGI1 autoimmune encephalitis for the purpose of supporting potential […]
Funded by the Autoimmune Encephalitis Alliance, Inc. (AE Alliance) IMPORTANT DATES Application Deadline: May 2, 2022 Award Notification: Early June 2022 The AE Alliance is pleased to announce the call for applications to our second annual AEA Community Seed grant program to support research focused on the diagnosis, management, and outcomes of individuals with autoimmune […]
We are excited to report that the ExTINGUISH Trial will start recruitment in January 2022. This trial is a Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor (NMDAR) Encephalitis and Assess Markers of Disease. This trial is the result of the dedication and hard work of Dr. […]
We are excited to report the first International Consensus Recommendations for the treatment of pediatric NMDAR Antibody Encephalitis. The paper results from the hard work, dedication, and collaboration between 27 international AE experts, led by Dr. Margherita Nosadini and Dr. Russell Dale. These treatment recommendations will be of great value to children affected by AE […]
Hashimoto encephalopathy (HE) is a rare disorder characterized by impaired brain function. The exact cause is unknown, but experts believe it to be an immune-mediated disorder or a disorder in which inflammation results from abnormal functioning of the immune system. People with HE have antithyroid antibodies in their bodies. However, it is unclear whether these […]
Dr. Amaia Muñoz Lopetegi (Hospital Clinic of Barcelona – Spain) has been awarded the AEA Community Seed Grant to investigate the Subclinical activity in anti-LGI1 encephalitis: diagnostic tests and prognostic implications. Learn more about her study and how this will affect those affected with autoimmune encephalitis. You have been awarded the AEA Seed Grant, can you tell us […]
Dr. Juna de Vries (Erasmus University – The Netherlands) has been awarded the AEA Community Seed Grant to investigate the Patient Reported Outcomes while Manipulating the Immune System in autoimmune Encephalitis. Learn more about her study and how this will affect those affected with autoimmune encephalitis. You have been awarded the AEA Community Seed Grant, can you tell […]
There are 7,000 rare diseases that affect millions of people. In the USAA disease is considered rare if fewer than 200,000 people are affected by it. Because these diseases are rare, a lot is still unknown. This creates problems in the management of rare diseases, like autoimmune encephalitis, because it leads to misdiagnosis, unmet treatment, […]
Dr. Soon-Tae Lee (Seoul National University Hospital – South-Korea) has been awarded the AEA Community Seed Grant to investigate the Development of optimal clinical approaches in seronegative autoimmune encephalitis. Learn more about his study and how this will affect those affected with seronegative autoimmune encephalitis (AE). You have been awarded the AEA Community Seed Grant, can […]
Over the past 20 years, significant advances have improved our understanding of diagnosis, treatment, and underlying causes of AE. The number of new publications has increased dramatically in the past few years. And here, we will share some recent advances made in the area of novel therapeutics and biomarker discovery. Sell at al., Autoimmune encephalitis: […]